Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter, Phase IIb Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Chronic Venous Ulcer (CVU)

NCT04971161 is registered in ClinicalTrials.gov with RHEACELL GmbH & Co. KG as lead sponsor.

NCT NCT04971161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04971161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter, Phase IIb Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Chronic Venous Ulcer (CVU)
Lead sponsor
RHEACELL GmbH & Co. KG
Phase
Phase 2
Overall status
Completed
Start date
August 18, 2021
Completion date
November 25, 2025
Enrollment
159 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

skin ulcer venous stasis chronic